Loading
Alyssum Therapeutics makes AT-1965, a drug packaged in tiny fat bubbles that blocks an enzyme in cancer cells so the tumour looks like a virus infection to the immune system, drawing in antibody-making B cells. It is in an early trial in people with advanced solid tumours.
Alyssum Therapeutics Inc, at 626 Massachusetts Avenue, Cambridge, Massachusetts, develops small molecules that act both as targeted therapies and as modulators of the immune response, with a focus on B cells. Its clinical candidate AT-1965 inhibits CMTR2, an RNA cap methyltransferase that marks RNA as self; the company says inhibiting it makes cancer-cell RNA resemble viral RNA, triggers an IFIT-driven antiviral response and recruits a B-cell response against the tumour. AT-1965 is given as a liposomal formulation that the company says was engineered with a patented quantum-mechanics, all-atom simulation platform to carry about three times the usual drug load; the work was published in Nature Nanotechnology in June 2026. A phase 1/2 study in advanced, refractory or recurrent solid tumours is under way, with particular interest in sarcoma, endometrial and vulvovaginal, and breast cancers. Its first registered cancer trial, NCT06234098, was posted on ClinicalTrials.gov in January 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/